Tyler O’Malley. Director of Evidence at Exagen Inc.

Tyler O’Malley

Director of Evidence Development

As Director of Evidence Development for Exagen, Tyler works cross-functionally to align unmet needs, patient journeys, and clinical evidence support for current and future diagnostic test offerings. Evidence development is crucial to ensuring broad access to innovative test offerings with the capacity to foster improved patient outcomes from individuals suffering from chronic autoimmune conditions. Additionally, Tyler has authored numerous publications in peer-reviewed journals and is the first author on one of the largest studies in lupus diagnostics.

Tyler O’Malley received his Bachelor of Science degree from Georgia Gwinnett College with summa cum laude distinction in biology with a biochemistry concentration. For the past 8 years, his work within R&D and Medical Affairs has ranged from medical science education, assay development, and clinical research coordination.


Bachelor of science (BSc) in biology with a biochemistry concentration from Georgia Gwinnett College

Selected Publications

Sciascia S, Bloch R, O'Malley T, Kammesheidt A, Alexander RV. Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d. Front Immunol. 2022 Aug 10;13:949919. doi: 10.3389/fimmu.2022.949919. PMID: 36032074; PMCID: PMC9399821.

O'Malley T, Xie F, Su Y, Clinton C, Zack DJ, Haechung C, Grabner M, Curtis JR. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus. J Manag Care Spec Pharm. 2022 Jul 1:1-12. doi: 10.18553/jmcp.2022.22039. Epub ahead of print. PMID: 35775579.

O'Malley T, Xie F, Su y, Clinton c, Zack D, Curtis J, Wegener J. The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10).

Petri M, Li J, Conklin J, O'Malley T, Ligayon J, Wolover L, Dervieux T. Role of Platelet C4d in Thrombosis and Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25. PMID: 31469249; PMCID: PMC6972605.

Arriens C, Alexander RV, Narain S, et al. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine 2020;7:e000377. doi: 10.1136/lupus-2019-000377.

Dervieux T, Kremer J, Conklin J, Brady K, Alexander R, O'Malley T, Shi J, Ibarra C, Mahler M, Weinblatt M, Weinstein A. Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors [abstract]. Arthritis Rheumatol. 2019; 71.

Wallace DJ, Alexander RV, O'Malley T, et al. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Science & Medicine 2019;6:e000349. doi: 10.1136/lupus-2019-000349.

Brady K, Qu Y, Stimson D, Apilado R, Vezza Alexander R, Reddy S, Chitkara P, Conklin J, O'Malley T, Ibarra C, Dervieux T. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases. J Appl Lab Med. 2019 Jul;4(1):40-49. doi: 10.1373/jalm.2018.027730. Epub 2019 Jan 11. PMID: 31639706.

Petri MA, Conklin J, O'Malley T, et al. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Science & Medicine 2019;6:e000318. doi: 10.1136/lupus-2019-000318

About Our Medical Review Process

Exagen content contributors bring extensive experience from lupus and autoimmune disease testing research to ensure our readers receive high-quality and safe health information.

Exagen articles are medically reviewed and medically fact-checked by rheumatology and autoimmune testing specialists to ensure that all factual statements about medical conditions, symptoms, procedures, tests, and standards of care are accurate and reflect current guidelines as well as the latest research. All topics are updated as new evidence becomes available and our editorial review process is complete.